Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703742 | 0.79 | TP53 (0.31) | — | |
| SCHEMBL1704162 | 0.79 | FPR2 (0.46) | ALDH1A1 | |
| SCHEMBL1167091 | 0.79 | KMT2A (0.40) | MEN1KMT2APKMALDH1A1 | |
| SCHEMBL27917153 | 0.78 | TXNRD1 (0.33) | — | |
| SCHEMBL1703731 | 0.77 | MAPT (0.38) | MEN1KMT2AMAPTNPSR1ALDH1A1 | |
| SCHEMBL9900188 | 0.76 | MAPT (0.31) | MAPTALDH1A1 | |
| SCHEMBL3717210 | 0.76 | PTGER1 (0.33) | KMT2A | |
| SCHEMBL27870396 | 0.75 | LMNA (0.32) | ALDH1A1 | |
| SCHEMBL27853597 | 0.75 | RAB9A (0.35) | MEN1KMT2AMAPTNPSR1ALDH1A1 | |
| SCHEMBL9900065 | 0.74 | RAB9A (0.38) | MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440555-B1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-18 | — | — | EP | disclosed |
| CN-102414207-B | Fluorinated aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-09-30 | — | — | CN | disclosed |
| US-8580831-B2 | Fluorinated aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
| EP-2440555-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143116-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | AFF1, SULT2A1, NAT1 | MEN1 854/4885KMT2A 187/4885MAPT 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.